Annals of Surgical Oncology

, Volume 25, Issue 5, pp 1410–1417 | Cite as

Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule

  • Trevor E. Angell
  • Chirag M. Vyas
  • Justine A. Barletta
  • Edmund S. Cibas
  • Nancy L. Cho
  • Gerard M. Doherty
  • Atul A. Gawande
  • Brooke E. Howitt
  • Jeffrey F. Krane
  • Ellen Marqusee
  • Kyle C. Strickland
  • Erik K. Alexander
  • Francis D. MooreJr.
  • Matthew A. Nehs
Endocrine Tumors
  • 88 Downloads

Abstract

Background

Diagnostic hemithyroidectomy (HT) is the most widely recommended surgical procedure for a nodule with indeterminate cytology; however, additional details may make initial total thyroidectomy (TT) preferable. We sought to identify patient-specific factors (PSFs) associated with initial TT in patients with indeterminate thyroid nodules.

Methods

Retrospective analysis of all patients with a thyroid nodule ≥ 1 cm and initial cytology of atypia of undetermined significance or suspicious for follicular neoplasm between 2012 and 2015 who underwent thyroidectomy. Medical records were reviewed for patient demographics, neck symptoms, nodule size, cytology, molecular test results, final histopathology, and additional PSFs influencing surgical management. Variables were analyzed to determine associations with the use of initial TT. Logistic regression analyses were performed to identify independent associations.

Results

Of 325 included patients, 182/325 (56.0%) had HT and 143/325 (44.0%) had TT. While patient age and sex, nodule size, and cytology result were not associated with initial treatment, five PSFs were associated with initial TT (p < 0.0001). These included contralateral nodules, hypothyroidism, fluorodeoxyglucose avidity on positron emission tomography scan, family history of thyroid cancer, and increased surgical risk. At least one PSF was present in 126/143 (88.1%) TT patients versus 47/182 (25.8%) HT patients (p < 0.0001). Multivariate logistic regression analysis demonstrated that these variables were the strongest independent predictor of TT (odds ratio 45.93, 95% confidence interval 18.80–112.23, p < 0.001).

Conclusions

When surgical management of an indeterminate cytology thyroid nodule was performed, several PSFs were associated with a preference by surgeons and patients for initial TT, which may be useful to consider in making decisions on initial operative extent.

Notes

Acknowledgements

None.

Disclosures

Trevor E. Angell has received research support from Veracyte Inc., and Erik K. Alexander is a consultant for Veracyte, Inc. Chirag M. Vyas, Justine A. Barletta, Edmund S. Cibas, Nancy L. Cho, Gerard M. Doherty, Atul A. Gawande, Brooke E. Howitt, Jeffrey F. Krane, Ellen Marqusee, Kyle C. Strickland, Francis D. Moore Jr, and Matthew Nehs have no relevant conflicts of interest to declare.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am. 2012;96:329–49.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007;111:508–16.CrossRefPubMedGoogle Scholar
  4. 4.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gharib H, Papini E, Paschke R, Buick DS, Valcavi R, Hegedus L, et al. AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest. 2010;33:51–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 2012;56:333–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117:143–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117:195–202.PubMedGoogle Scholar
  9. 9.
    Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19:1159–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Adam MA, Thomas S, Youngwirth L, Hyslop T, Reed SD, Scheri RP, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265:402–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Shapiro S, Pharaon M, Kellermeyer B. Cost-effectiveness of gene expression classifier testing of indeterminate thyroid nodules utilizing a real cohort comparator. Otolaryngol Head Neck Surg. 2017;157:596–601.CrossRefPubMedGoogle Scholar
  14. 14.
    Hang JF, Westra WH, Cooper DS, Ali SZ. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier. Cancer. 2017;125:683–91.Google Scholar
  15. 15.
    Yip L, Sosa JA. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment. JAMA Surg. 2016;151:663–70.Google Scholar
  16. 16.
    Yip L, Wharry LI, Armstrong MJ, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg 2014;260:163–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Patel SG, Carty SE, McCoy KL, et al. Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery. 2017;161:168–75.CrossRefPubMedGoogle Scholar
  18. 18.
    Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2011;96:E1719–26.CrossRefPubMedGoogle Scholar
  19. 19.
    Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012;22:996–1001.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lee L, How J, Tabah RJ, Mitmaker EJ. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. J Clin Endocrinol Metab. 2014;99:2674–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Labourier E. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology. Clin Endocrinol (Oxf) 2016;85:624–31.CrossRefGoogle Scholar
  22. 22.
    Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery. 2016;159:118–26.CrossRefPubMedGoogle Scholar
  23. 23.
    Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The impact of non-invasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25:987–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Howitt BE, Chang S, Eszlinger M, Paschke R, Drage MG, Krane JF, Barletta JA. Fine-needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2015;144:850–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Maletta F, Massa F, Torregrossa L, et al. Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol. 2016;54:134–42.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Trevor E. Angell
    • 1
  • Chirag M. Vyas
    • 1
  • Justine A. Barletta
    • 2
  • Edmund S. Cibas
    • 2
  • Nancy L. Cho
    • 3
  • Gerard M. Doherty
    • 3
  • Atul A. Gawande
    • 3
  • Brooke E. Howitt
    • 2
  • Jeffrey F. Krane
    • 2
  • Ellen Marqusee
    • 1
  • Kyle C. Strickland
    • 2
  • Erik K. Alexander
    • 1
  • Francis D. MooreJr.
    • 3
  • Matthew A. Nehs
    • 3
  1. 1.The Thyroid Section, Division of Endocrinology, Diabetes and HypertensionThe Brigham & Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Department of PathologyThe Brigham & Women’s Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Department of SurgeryThe Brigham & Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations